StemMedical’s core manufacturing competencies are focused on producing and expanding very high quantities of potent and affordable MSCs.
StemMedical can produce and harvest 12-16 billion ASCs from 100 ml of adipose tissue over 2 weeks using a scalable 3D cell culturing process instead of a manual non-scalable 2D cell process over several more weeks (as is currently industry standard).
Production takes place at our production facility outside Copenhagen. To expand capacity, blueprints have been made for a 2,500 sqm manufacturing site, designed for Good Manufacturing Practices (GMP) readiness, and with a planned capacity of over 7,000 batches per year. Work is currently in preparatory stage.
